Latest 10-K annual reports

Arcus Biosciences reports increased net losses in 2025, discontinues a Phase 3 trial, but strengthens its financial position with new equity and debt financing.

IonQ, a quantum platform company, reported a significant increase in net losses to $510.4 million in 2025, driven by aggressive R&D and strategic acquisitions, while revenue more than doubled to $130.0 million.

Revolution Medicines reports significant clinical advancements for its RAS(ON) inhibitor pipeline, including multiple FDA Breakthrough Therapy Designations, alongside increased R&D expenses and a net loss of $1.13 billion for 2025.

Edwards Lifesciences reported a significant increase in net sales for 2025, driven by strong performance in its TAVR and TMTT product groups, despite a decrease in net income due to higher operational and litigation expenses.

QuantumScape's 2025 10-K details continued solid-state battery development, key partnerships, and significant financial losses as it targets commercialization.

Net Lease Office Properties reports increased FFO and AFFO, significant debt reduction, and substantial special cash distributions amidst ongoing asset disposition strategy.

CareDx, a precision medicine company, reported a 14% increase in total revenue to $379.8 million for fiscal year 2025, alongside a net loss of $21.4 million, while successfully remediating a material weakness in internal controls and settling a securities class action.

First Financial Bankshares, Inc. reported a 13.45% increase in net earnings for 2025, driven by robust net interest income and asset growth, despite a significant credit loss from fraudulent activity.

Carlsmed, Inc. achieved significant revenue growth and expanded its AI-enabled personalized spine surgery platform into cervical fusion, backed by strong clinical evidence and favorable reimbursement updates.

The Honest Company reported a 1.9% revenue decline and a wider net loss for 2025 as it exited DTC, apparel and Canada, while unveiling a $25 million share repurchase and pushing ahead with its Powering Honest Growth plan.

Pebblebrook Hotel Trust reports mixed 2025 results with urban market recovery, resilient leisure demand, and strategic capital actions amidst regional challenges and an impairment loss.

MYR Group Inc. reports a significant surge in 2025 net income and gross profit, driven by robust demand in its Transmission & Distribution and Commercial & Industrial segments.

Planet Fitness, Inc. announced robust financial and operational performance for fiscal year 2025, driven by increased membership, club expansion, and higher revenue across all segments.

Arcutis Biotherapeutics reports significant revenue growth for its ZORYVE product line in 2025, driven by expanded indications and commercial launches, despite ongoing net losses and a terminated promotion agreement.

First Business Financial Services, Inc. reported a significant increase in net income and total assets for the fiscal year ended December 31, 2025, driven by loan growth and diversified revenue streams.

Celldex Therapeutics' 2025 annual report details significant clinical advancements for Barzolvolimab and CDX-622, alongside executive compensation updates and financial performance.

Catalyst Pharmaceuticals reported significant revenue and net income growth in its 2025 annual report, primarily fueled by the successful commercialization of AGAMREE and continued FIRDAPSE sales, despite generic competition for FYCOMPA.

MercadoLibre, the leading online commerce and fintech ecosystem in Latin America, reported significant revenue and user growth in 2025, driven by its e-commerce and Mercado Pago platforms, despite a decline in operating margins.

APi Group Corporation announced robust financial results for 2025, driven by strong revenue growth, margin expansion, and strategic acquisitions, alongside a significant share repurchase program.

Simmons First National Corporation reported a net loss of $397.6 million for 2025, driven by a strategic balance sheet repositioning that included a significant securities sale loss, despite achieving strong adjusted earnings and capital ratios.

Fidelity Ethereum Fund reports significant asset growth in 2025, reaching $2.2 billion, despite a 10.86% decline in ether's price and market volatility.

Fidelity Wise Origin Bitcoin Fund reports a 6.56% decrease in Net Asset Value per Share for 2025, with net assets falling to $17.6 billion amidst bitcoin price volatility and increased regulatory scrutiny.

Pacific Biosciences of California, Inc. reports a strategic shift towards HiFi sequencing, an asset sale, and a net loss of $546.4 million for fiscal year 2025, alongside a decrease in cash and investments.

Ally Financial Inc. reported a significant increase in net income from continuing operations to $852 million in 2025, driven by lower credit losses and improved net financing revenue, despite strategic divestitures and market pressures.

Xencor, a clinical-stage biopharmaceutical company, reported a net loss of $91.9 million in 2025, driven by increased R&D, while advancing multiple oncology and autoimmune drug candidates and remediating prior material weaknesses in internal controls.

ARKO Corp. reports mixed 2025 results, with declining revenues but increased operating income, driven by strategic retail conversions and a focus on higher-margin offerings, alongside the successful IPO of its wholesale subsidiary, ARKO Petroleum Corp.

McGrath RentCorp reported a 4% revenue increase to $944.2 million in 2025, but net income decreased to $156.3 million due to a non-recurring merger termination gain in the prior year, while underlying operational performance improved.

MiMedx Group, Inc. achieved significant revenue and net income growth in 2025, driven by product expansion, but faces substantial headwinds from new Medicare reimbursement policies effective January 2026.

LifeStance Health Group, Inc. reported a significant financial turnaround in 2025, achieving net income and positive operating income, driven by strong revenue growth and increased patient visits.

Flowers Foods reports a 3.0% sales increase in Fiscal 2025, driven by the Simple Mills acquisition and an extra week, despite significant impairment charges and a challenging fresh packaged bread market.